Evidence map›Paper›PMID 41616023›Full record

ArticlePloS one2026

The autonomy paradox in AI-generated content adoption: Creative-specific alternative to TAM model in China's micro-short drama industry.

Chao Tang

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Chao TangSchool of Animation, Jinling Institute of Technology, Nanjing, Jiangsu, China.ORCID https://orcid.org/0009-0003-6744-1759

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In China's booming micro-short drama industry, Artificial Intelligence Generated Content (AIGC) presents creators with an 'autonomy paradox': improving efficiency while sparking fears of lost control, amplified by collectivist culture that heightens tensions between AI-driven productivity and loss of autonomy. Based on a mixed-methods study of 607 micro-short drama creators, this research proposes and tests the Creative Industries Technology Acceptance Model (CITAM), which builds upon TAM foundations while adapting constructs for creative contexts to reveal key dynamics in adoption intentions. Building upon TAM theoretical foundations while introducing innovation compatibility (IC) and creative autonomy retention (CAR), CITAM is grounded in Diffusion of Innovations and Self-Determination Theory to address both rational and psychological adoption factors in creative contexts. Using a mixed methods approach with SEM in 607 surveys and 10 in-depth interviews, the results reveal that CAR positively influences AIGC adoption through IC as a mediator, while CAR negatively moderates the positive influence of IC on adoption intentions, highlighting a modest but significant psychological tension. Qualitative insights on 'Creativity Amplification' complement this, showing that creators perceive AIGC as an idea enhancer, not a replacement for the essential 'human spark.' CITAM provides a customized extension of TAM for creative industries, offering practical guidance. The findings can help developers design tools that preserve the agency of the creator and inform policy makers about balancing AIGC innovation with creator rights. These discoveries offer an initial framework for the adoption of ethical AI in the global creative economy, calling for cross-cultural validation to improve generalizability in AI-driven creative ecosystems.

Indexed as

Artificial IntelligenceCreativityIndustryChinaHumans

Identifiers

PMID41616023
PMCPMC12858070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.